AbbVie's forward-looking guidance projects robust growth for 2025 and beyond, with mid-single-digit revenue growth anticipated. The ex-Humira platform is expected to surpass previous peak revenues, with Skyrizi and Rinvoq projected to contribute significantly. Neuroscience and oncology segments are poised for continued expansion. Despite challenges in the aesthetics segment, a high single-digit CAGR is expected through 2029. AbbVie aims to sustain growth through its diverse portfolio and strategic pipeline advancements.